Skip to Content
Merck
  • Abnormal excitability and episodic low-frequency oscillations in the cerebral cortex of the tottering mouse.

Abnormal excitability and episodic low-frequency oscillations in the cerebral cortex of the tottering mouse.

The Journal of neuroscience : the official journal of the Society for Neuroscience (2015-04-10)
Samuel W Cramer, Laurentiu S Popa, Russell E Carter, Gang Chen, Timothy J Ebner
ABSTRACT

The Ca(2+) channelopathies caused by mutations of the CACNA1A gene that encodes the pore-forming subunit of the human Cav2.1 (P/Q-type) voltage-gated Ca(2+) channel include episodic ataxia type 2 (EA2). Although, in EA2 the emphasis has been on cerebellar dysfunction, patients also exhibit episodic, nonmotoric abnormalities involving the cerebral cortex. This study demonstrates episodic, low-frequency oscillations (LFOs) throughout the cerebral cortex of tottering (tg/tg) mice, a widely used model of EA2. Ranging between 0.035 and 0.11 Hz, the LFOs in tg/tg mice can spontaneously develop very high power, referred to as a high-power state. The LFOs in tg/tg mice are mediated in part by neuronal activity as tetrodotoxin decreases the oscillations and cortical neuron discharge contain the same low frequencies. The high-power state involves compensatory mechanisms because acutely decreasing P/Q-type Ca(2+) channel function in either wild-type (WT) or tg/tg mice does not induce the high-power state. In contrast, blocking l-type Ca(2+) channels, known to be upregulated in tg/tg mice, reduces the high-power state. Intriguingly, basal excitatory glutamatergic neurotransmission constrains the high-power state because blocking ionotropic or metabotropic glutamate receptors results in high-power LFOs in tg/tg but not WT mice. The high-power LFOs are decreased markedly by acetazolamide and 4-aminopyridine, the primary treatments for EA2, suggesting disease relevance. Together, these results demonstrate that the high-power LFOs in the tg/tg cerebral cortex represent a highly abnormal excitability state that may underlie noncerebellar symptoms that characterize CACNA1A mutations.

MATERIALS
Product Number
Brand
Product Description

Supelco
Melting point standard 235-237°C, analytical standard
Sigma-Aldrich
Pyridine hydrochloride, purum, ≥98.0% (AT)
Supelco
Indomethacin, Pharmaceutical Secondary Standard; Certified Reference Material
Indomethacin, European Pharmacopoeia (EP) Reference Standard
Acetazolamide, European Pharmacopoeia (EP) Reference Standard
Caffeine for system suitability, European Pharmacopoeia (EP) Reference Standard
Supelco
4-Aminopyridine, PESTANAL®, analytical standard
Sigma-Aldrich
Pyridine hydrochloride, 98%
Supelco
Chloromethane solution, 200 μg/mL in methanol, analytical standard
Sigma-Aldrich
4-Aminopyridine, 98%
Sigma-Aldrich
Indole, ≥99%, FG
Sigma-Aldrich
4-Aminopyridine, ≥99%
Sigma-Aldrich
Indole, ≥99%
Sigma-Aldrich
Indomethacin, meets USP testing specifications
Sigma-Aldrich
Indomethacin, 98.5-100.5% (in accordance with EP)
Sigma-Aldrich
Acetazolamide, ≥99%, powder
Sigma-Aldrich
DL-2-Amino-5-phosphonopentanoic acid, solid
Sigma-Aldrich
Chloromethane solution, 1.0 M in diethyl ether
Sigma-Aldrich
Chloromethane solution, 1.0 M in tert-butyl methyl ether, anhydrous
Acetazolamide for system suitability, European Pharmacopoeia (EP) Reference Standard
USP
Acetazolamide, United States Pharmacopeia (USP) Reference Standard
USP
Indomethacin, United States Pharmacopeia (USP) Reference Standard
Supelco
Caffeine, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Supelco
Caffeine Melting Point Standard, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Caffeine melting point standard, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Caffeine, anhydrous, 99%, FCC, FG
Sigma-Aldrich
Caffeine, anhydrous, tested according to Ph. Eur.
Sigma-Aldrich
Monoclonal Anti-α-Tubulin antibody produced in mouse, ascites fluid, clone B-5-1-2
Sigma-Aldrich
DNQX, ≥98% (TLC)
Sigma-Aldrich
Caffeine, meets USP testing specifications, anhydrous